Keryx Biopharmaceuticals (KERX) Shares Bought by Bank of New York Mellon Corp
Bank of New York Mellon Corp increased its position in Keryx Biopharmaceuticals (NASDAQ:KERX) by 1.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 973,229 shares of the biopharmaceutical company’s stock after buying an additional 10,175 shares during the period. Bank of New York Mellon Corp owned 0.82% of Keryx Biopharmaceuticals worth $6,910,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Fox Run Management L.L.C. bought a new stake in Keryx Biopharmaceuticals during the third quarter worth approximately $101,000. Principal Financial Group Inc. increased its stake in Keryx Biopharmaceuticals by 4.2% during the second quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 590 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in Keryx Biopharmaceuticals by 51.8% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 16,495 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 5,628 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in Keryx Biopharmaceuticals during the second quarter worth approximately $183,000. Finally, Legal & General Group Plc increased its stake in Keryx Biopharmaceuticals by 8.5% during the second quarter. Legal & General Group Plc now owns 28,205 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 2,220 shares during the last quarter. Institutional investors own 64.82% of the company’s stock.
Several equities research analysts have weighed in on the company. Zacks Investment Research cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 8th. ValuEngine cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 21st. Finally, Stifel Nicolaus cut their target price on Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating on the stock in a research note on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $7.35.
Keryx Biopharmaceuticals (NASDAQ:KERX) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $15.00 million for the quarter, compared to the consensus estimate of $18.88 million. Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. The company’s quarterly revenue was up 138.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.39) EPS. equities analysts predict that Keryx Biopharmaceuticals will post -1.36 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Keryx Biopharmaceuticals (KERX) Shares Bought by Bank of New York Mellon Corp” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/30/keryx-biopharmaceuticals-kerx-shares-bought-by-bank-of-new-york-mellon-corp.html.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.